BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 32874406)

  • 1. Isolated blast crisis relapse in the central nervous system of a patient treating for a chronic myelogenous leukemia.
    Boudiaf H; Ezziane K; Rouis NO; Himrane M; Hakem S; Benchabane H; Boukhelal H; Arous R; Chikhi L
    Pan Afr Med J; 2020; 36():142. PubMed ID: 32874406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mixed phenotype (T/B/myeloid) extramedullary blast crisis as an initial presentation of chronic myelogenous leukemia.
    Qing X; Qing A; Ji P; French SW; Mason H
    Exp Mol Pathol; 2018 Apr; 104(2):130-133. PubMed ID: 29501750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate.
    Matsuda M; Morita Y; Shimada T; Miyatake J; Hirase C; Tanaka M; Tatsumi Y; Maeda Y; Kanamaru A
    Int J Hematol; 2005 May; 81(4):307-9. PubMed ID: 15914360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bilineal Extramedullary Blast Crisis as an Initial Presentation of Chronic Myeloid Leukemia: A Case Report and Literature Review.
    Gao X; Li J; Wang L; Lin J; Jin H; Xu Y; Wang N; Zhao Y; Liu D; Yu L; Wang Q
    Am J Case Rep; 2016 Oct; 17():793-798. PubMed ID: 27784881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic Myelogenous Leukemia Relapse Presenting With Central Nervous System Blast Crisis and Bilateral Optic Nerve Infiltration.
    Mbekeani JN; Abdel Fattah M; Al Nounou RM; Chebbo W; Dogar MA
    J Neuroophthalmol; 2016 Mar; 36(1):73-7. PubMed ID: 26628337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic Myeloid Leukemia with cryptic Philadelphia translocation and extramedullary B-lymphoid blast phase as an initial presentation.
    Soliman DS; Amer AM; Mudawi D; Al-Sabbagh Z; Alkuwari E; Al-Sabbagh A; Ibrahim F; Yassin MA
    Acta Biomed; 2018 Apr; 89(3-S):38-44. PubMed ID: 29633732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report.
    Altintas A; Cil T; Kilinc I; Kaplan MA; Ayyildiz O
    J Neurooncol; 2007 Aug; 84(1):103-5. PubMed ID: 17318411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib.
    Morel F; Bris MJ; Herry A; Calvez GL; Marion V; Abgrall JF; Berthou C; Braekeleer MD
    Eur J Haematol; 2003 Apr; 70(4):235-9. PubMed ID: 12656747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
    Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D
    J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged Survival of a Patient with Chronic Myeloid Leukemia in Accelerated Phase with Recurrent Isolated Central Nervous System Blast Crisis.
    Bin Salman AA; Zaidi ARZ; Altaf SY; AlShehry NF; Tailor IK; Motabi IH; Zaidi SZA
    Am J Case Rep; 2020 Sep; 21():e922971. PubMed ID: 32920590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extramedullary blastic crisis in abdominal lymph nodes in a patient with chronic myelogenous leukemia on imatinib.
    Shune L; Cayci Z; Rogosheske J; Brunstein C; Ustun C
    Leuk Res; 2012 Jun; 36(6):e131-2. PubMed ID: 22444689
    [No Abstract]   [Full Text] [Related]  

  • 13. Pathobiology of lymphoid and myeloid blast crisis and management issues.
    Ilaria RL
    Hematology Am Soc Hematol Educ Program; 2005; ():188-94. PubMed ID: 16304379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Philadelphia-chromosome-positive T-lymphoblastic leukemia: acute leukemia or chronic myelogenous leukemia blastic crisis.
    Raanani P; Trakhtenbrot L; Rechavi G; Rosenthal E; Avigdor A; Brok-Simoni F; Leiba M; Amariglio N; Nagler A; Ben-Bassat I
    Acta Haematol; 2005; 113(3):181-9. PubMed ID: 15870488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spontaneous reversion from blast to chronic phase after withdrawal of imatinib mesylate in a patient with chronic myelogenous leukemia.
    Liu NS; O'Brien S
    Leuk Lymphoma; 2002 Dec; 43(12):2413-5. PubMed ID: 12613534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extramedullary tumors of myeloid blasts in adults as a pattern of relapse following allogeneic bone marrow transplantation.
    Koc Y; Miller KB; Schenkein DP; Daoust P; Sprague K; Berkman E
    Cancer; 1999 Feb; 85(3):608-15. PubMed ID: 10091734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
    Cohen MH; Johnson JR; Pazdur R
    Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid.
    Bornhauser M; Jenke A; Freiberg-Richter J; Radke J; Schuler US; Mohr B; Ehninger G; Schleyer E
    Ann Hematol; 2004 Jun; 83(6):401-2. PubMed ID: 14673623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration.
    Campbell LJ; Patsouris C; Rayeroux KC; Somana K; Januszewicz EH; Szer J
    Cancer Genet Cytogenet; 2002 Nov; 139(1):30-3. PubMed ID: 12547154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.